Categories Consumer, Earnings

Darden Restaurants (DRI) withdraws FY20 outlook and cancels dividend on COVID-19 concerns

Darden exceeds Q3 2020 estimates; fourth quarter to date same-restaurant sales decline

Darden Restaurants (NYSE: DRI) surpassed third-quarter 2020 earnings and sales estimates. The dine-in restaurant company withdrew its fiscal 2020 guidance and suspended quarterly dividend amid coronavirus outbreak.

DRI shares, which traded up immediately after the earnings announcement, lost the momentum and traded in the negative territory in the pre-market trading session.

The company posted earnings of $1.89 per share on sales of $2.35 billion for the third quarter of 2020. The market had projected Darden to report earnings of $1.88 per share on revenue of $2.32 billion.

Sales increased 4.5% in the three months ended February 23, 2020, helped by the same-restaurant sales growth of 2.3% and the addition of 40 new restaurants.

Darden pulled out its full-year financial outlook for fiscal 2020 and is fully drawing on its $750 million credit facility. The Board of Directors also suspended the quarterly cash dividend.

These actions were taken by the company as there was a significant reduction in effective restaurant seating capacity and other restrictions mandated by state and local governments in response to COVID-19 outbreak.

When Darden reported the second-quarter results, it guided fiscal 2020 adjusted EPS from continuing operations in the range of $6.30-6.45. The company had projected sales to grow between 5.3% and 6.3% and same-restaurant sales growth of 1-2% for the fiscal year 2020.

Related: How much of a hit could Darden (DRI) take from the coronavirus outbreak?

For the fourth quarter to date through March 15, Darden same-restaurant sales declined 5.9%. Same-restaurant sales were +3.0%, -0.2%, and -20.6% for the first three weeks of the quarter, respectively.

DRI stock, which hit a new 52-week low ($26.15) yesterday, has slumped 69% so far this year.

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top